Tisdag 13 Maj | 14:59:17 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-02-11 10:30 Bokslutskommuniké 2025
2025-11-12 08:30 Kvartalsrapport 2025-Q3
2025-08-27 08:30 Kvartalsrapport 2025-Q2
2025-05-30 N/A X-dag ordinarie utdelning QLIFE 0.00 SEK
2025-05-28 N/A Årsstämma
2025-05-20 08:30 Kvartalsrapport 2025-Q1
2025-03-21 - Extra Bolagsstämma 2025
2025-02-12 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-07-30 - Split QLIFE 2000:1
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-08 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 - Årsstämma
2024-02-08 - Bokslutskommuniké 2023
2024-01-16 - Extra Bolagsstämma 2023
2023-11-13 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 - Årsstämma
2023-03-24 - Extra Bolagsstämma 2022
2023-02-16 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-08 - Kvartalsrapport 2021-Q3
2021-08-16 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Extra Bolagsstämma 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2021-11-29 11:34:39

Qlife has recruited Kasper Damgaard Rousøe as new Chief Financial Officer (CFO) for Qlife Holding AB and subsidiary Qlife Aps. Kasper comes most recently from Phase One A/S and will begin his new role no later than 1 March 2022. Current CFO in Qlife Aps Lars Bangsgaard has decided to retire from his position, and part-time CFO in Qlife Holding AB Henrik Ljung will end his assignment at the end of Q1 2022.

Kasper Rousøe has more than 20 years of experience from leading roles in the financial area, most recently from Phase One A/S. He has previously been CFO and Finance Director in Bauer Media Group, Mono Solutions and Designit A/S, and has through his roles gained international experience from the software, hardware, and creative industries. Kasper hold a M. Sc. in Economics from Copenhagen University and an EMBA from Lausanne in Switzerland.

"I am very happy to welcome Kasper to Qlife. In addition to solid expertise in finance, he has broad knowledge of manufacturing, procurement and IT products and processes. Qlife is in a very expansive phase, and Kasper will be an important part of the company's group management and I look forward to working with him" says Qlife's CEO Thomas Warthoe.

"It feels incredibly exciting to be a part of Qlife and it's mission to revolutionize the market for clinical biomarker and virus tests with it's game-changing potential. I look forward to working with Qlife's team in realising the commercial potential and growth opportunities" says Kasper Rousøe.

Lars Bangsgaard is part of the original founder's group and will remain a major share owner in Qlife (7.8%).